Barriers to prescribing cannabis‐based medicines
Sign Up to like & getrecommendations! Published in 2019 at "Prescriber"
DOI: 10.1002/psb.1774
Abstract: Last November, the government moved cannabis‐based medicinal products out of Schedule 1 into Schedule 2 of the Misuse of Drugs Regulations, meaning they can now legally be prescribed. However, conflicting advice from different authorities, sourcing… read more here.
Keywords: prescribing cannabis; based medicines; barriers prescribing; cannabis based ... See more keywords
Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
Sign Up to like & getrecommendations! Published in 2022 at "Internal medicine journal"
DOI: 10.1111/imj.15700
Abstract: BACKGROUND Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, became government subsidised in Australia for patients with ASCVD requiring… read more here.
Keywords: subtilisin kexin; kexin type; barriers prescribing; proprotein convertase ... See more keywords